Dysfunction of two lysosome degradation pathways of α-synuclein in Parkinson's disease: Potential therapeutic targets?

Neuroscience Bulletin

Volumn 28, Issue 5, 2012, Pages 649-657

  Jiang, Tian Fang ^a   Chen, Sheng Di ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

synuclein; Neurodegenerative disease; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; BECLIN 1; GANGLIOSIDE; HEAT SHOCK PROTEIN 90; RAPAMYCIN;

AUTOPHAGOSOME; AUTOPHAGY; BIOACCUMULATION; CELL AGGREGATION; CELL INTERACTION; CELL TRANSPORT; DEGRADATION KINETICS; DOPAMINERGIC NERVE CELL; ENDOCYTOSIS; EXOCYTOSIS; EXTERNALIZATION; GENE OVEREXPRESSION; HUMAN; INTERNALIZATION; LEWY BODY; LYSOSOME; MICROENVIRONMENT; MICROGLIA; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; POINT MUTATION; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; REVIEW; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; ANIMALS; ANTIPARKINSON AGENTS; AUTOPHAGY; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION; HUMANS; LYSOSOMES; PARKINSON DISEASE; POINT MUTATION; SIGNAL TRANSDUCTION;

EID: 84871406044     PISSN: 16737067     EISSN: 19958218     Source Type: Journal    
DOI: 10.1007/s12264-012-1263-1     Document Type: Review

References (40)

1. Beyer K, Domingo-Sábat M, Lao JI, Carrato C, Ferrer I, Ariza A. Identification and characterization of a new α-synuclein isoform and its role in Lewy body diseases. Neurogenetics 2008, 9(1): 15-23. (Pubitemid 351170166)
2. Beyer K, Domingo-Sàbat M, Humbert J, Carrato C, Ferrer I, Ariza A. Differential expression of α-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. Neurogenetics 2008, 9(3): 163- 172.
3. Mori F, Tanji K, Yoshimoto M, Takahashi H, Wakabayashi K. Demonstration of α-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment. Exp Neurol 2002, 176(1): 98-104. (Pubitemid 34762109)
4. Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 2005, 25(25): 6016-6024. (Pubitemid 40911433)
5. Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, Qureshi MM, et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006, 349(1): 162-166. (Pubitemid 44331776)
6. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, et al. Alpha-Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006, 313 (5785): 324-328. (Pubitemid 44480951)
7. Larsen KE, Schmitz Y, Troyer MD, Mosharov E, Dietrich P, Quazi AZ, et al. α-Synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 2006, 26(46): 11915-11922. (Pubitemid 44772102)
8. Chandra S, Fornai F, Kwon HB, Yazdani U, Atasoy D, Liu X, etal. Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc Natl Acad Sci U S A 2004, 101(41): 14966-14971. (Pubitemid 39410782)
9. Sandal M, Valle F, Tessari I, Mammi S, Bergantino E, Musiani F, et al. Conformational equilibria in monomeric α-synuclein at the single-molecule level. PLoS Biol 2008, 6 (1): e6.
10. Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M. Microglia acquire distinct activation profiles depending on the degree of alpha-Synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One 2010, 5: e8784.
11. Gu XL, Long CX, Sun L, Xie C, Lin X, Cai H. Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice. Mol Brain 2010, 3: 12.
12. Lee HJ, Suk JE, Bae EJ, Lee JH, Paik SR, Lee SJ. Assemblydependent endocytosis and clearance of extracellular α-synuclein. Int J Biochem Cell Biol 2008, 40(9): 1835-1849.
13. Su XM, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ. Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging 2008, 29(11): 1690-1701.
14. Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, et al. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci 2010, 30(20): 6838-6851.
15. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006, 20(3): 419-425. (Pubitemid 44933318)
16. Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, et al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J Neurosci 2009, 29(43): 13578-13588.
17. Roodveldt C, Labrador-Garrido A, Gonzalez-Rey E, Fernandez- Montesinos R, Caro M, Lachaud CC, et al. Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and parkinson's disease-linked mutants. PLoS One 2010, 5(10): e13481.
18. Zhang W, Wang TG, Pei Z, Miller DS, Wu X, Block ML, et al. Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 2005, 19(6): 533-542. (Pubitemid 40471244)
19. Winslow AR, Chen CW, Corrochano S, Acevedo-Arozena A, Gordon DE, Peden AA, et al. α-Synuclein impairs macroautophagy: implications for Parkinson's disease. J Cell Biol 2010, 190(6): 1023-1037.
20. Soper JH, Kehm V, Burd CG, Bankaitis VA, Lee VM. Aggregation of α-synuclein in S. cerevisiae is associated with defects in endosomal trafficking and phospholipid biosynthesis. J Mol Neurosci 2011, 43(3): 391-405.
21. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010, 65(1): 66-79.
22. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, et al. Inclusion formation and neuronal cell death through neuron-toneuron transmission of alpha-Synuclein. Proc Natl Acad Sci U S A 2009, 106(31): 13010-13015.
23. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008, 451(7182): 1069-1075. (Pubitemid 351317450)
24. Moreau K, Ravikumar B, Renna M, Puri C, Rubinsztein DC. Autophagosome precursor maturation requires homotypic fusion. Cell 2011, 146(2): 303-317.
25. Mizushima N. The role of the Atg1/ULK1 complex in autophagy regulation. Cell Biol 2010, 22(2): 132-139.
26. Wirawan E, Berghe TV, Lippens S, Agostinis P, Vandenabeele P. Autophagy: for better or for worse. Cell Res 2011, 22(1): 43-61.
27. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov 2007, 6(4): 304-312. (Pubitemid 46505881)
28. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132(1): 27-42.
29. Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 2008, 118(2): 777- 788.
30. Xilouri M, Vogiatzi T, Vekrellis K, Park D, Stefanis L. Abberant α-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS One 2009, 4(5): e5515.
31. Crews L, Spencer B, Desplats P, Patrick C, Paulino A, Rockenstein E, et al. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of α-synucleinopathy. PLoS One 2010, 5(2): e9313.
32. Huang Y, Chegini F, Chua G, Murphy K, Gai WP, Halliday GM. Macroautophagy in sporadic and the genetic form of Parkinson's disease with the A53T alpha-synuclein mutation. Transl Neurodegener 2012, 1: 2.
33. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperonemediated autophagy. Science 2004, 305(5688): 1292-1295. (Pubitemid 39129234)
34. Alvarez-Erviti L, Seow Y, Schapira AH, Gardiner C, Sargent IL, Wood MJ, et al. Lysosomal dysfunction increases exosome-mediated alpha-Synuclein release and transmission. Neurobiol Dis 2011, 42(3): 360-367.
35. Yuyama K, Yamamoto N, Yanagisawa K. Accelerated release of exosome-associated GM1 ganglioside (GM1) by endocytic pathway abnormality: another putative pathway for GM1-induced amyloid fibril formation. J Neurochem 2008, 105(1): 217-224. (Pubitemid 351441638)
36. Liu J, Zhang JP, Shi M, Quinn T, Bradner J, Beyer R, et al. Rab11a and HSP90 regulate recycling of extracellular α-synuclein. J Neurosci 2009, 29(5): 1480-1485.
37. Zabrocki P, Bastiaens I, Delay C, Bammens T, Ghillebert R, Pellens K, et al. Phosphorylation, lipid raft interaction and trafficof α-synuclein in a yeast model for Parkinson. Biochim Biophys Acta 2008, 1783(10): 1767-1780.
38. Mocchetti I. Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins. Cell Mol Life Sci 2005, 62(19-20): 2283-2294. (Pubitemid 41500544)
39. Wei J, Fujita M, Nakai M, Waragai M, Sekigawa A, Sugama S, et al. Protective role of endogenous gangliosides for lysosomal pathology in a cellular model of synucleinopathies. Am J Pathol 2009, 174(5): 1891-1909.
40. Winslow AR, Rubinsztein DC. The Parkinson disease protein α-synuclein inhibits autophagy. Autophagy 2011, 7(4): 429-431.